More severe infectious complications in CLL patients treated with fludarabine, cyclophosphamide, rituximab (FCR) in comparison to bendamustin plus rituximab (BR): Results of the interim-analysis of the CLL10 trial of the German CLL Study Group

被引：0

作者：

Langerbeins, P. ^{[1
]}

Busch, R. ^{[2
]}

Schweighofer, C. D. ^{[1
]}

Mueller, C. ^{[1
]}

Fischer, K. ^{[1
]}

Fink, A. -M. ^{[1
]}

Cramer, P. ^{[1
]}

Faetkenheuer, G. ^{[1
]}

Hartmann, P. ^{[1
]}

Stilgenbauer, S. ^{[3
]}

Boettcher, S. ^{[4
]}

Wendtner, C. -M. ^{[5
]}

Hallek, M. ^{[1
]}

Eichhorst, B. ^{[1
]}

机构：

[1] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany

[2] Tech Univ Munich, Inst Med Stat & Epidemiol, D-80290 Munich, Germany

[3] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany

[4] Univ Hosp Schleswig Holstein, Dept Med 2, Kiel, Germany

[5] Klinikum Schwabing, Dept Internal Med 1, Munich, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V572

引用

页码：185 / 185

页数：1

共 50 条

[31] Quantitative MRD Assessments Predict Progression Free Survival in CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab - a Prospective Analysis in 471 Patients from the Randomized GCLLSG CLL8 Trial
Boettcher, Sebastian
Fischer, Kirsten
Stilgenbauer, Stephan
Busch, Raymonde
Fingerle-Rowson, Guenter
Fink, Anna-Maria
Doehner, Hartmut
Hallek, Michael
Kneba, Michael
Ritgen, Matthias
BLOOD, 2008, 112 (11) : 125 - 126
[32] Cyclophosphamide, Adriamycin, Vincristine and Prednisone Plus Rituximab (CHOP-R) in Fludarabine (F) Refractory Chronic Lymphocytic Leukemia (CLL) or CLL with Autoimmune Cytopenia (AIC) or Richter's Transformation (RT): Final Analysis of a Phase II Study of the German CLL Study Group
Jenke, Petra
Eichhorst, Barbara
Busch, Raymonde
Anheier, Nadine
Duehrsen, Ulrich
Duerig, Jan
Dreyling, Martin H.
Bergmann, Manuela
Goebeler, Maria Elisabeth
Hurts, Hans Juergen
Stauch, Martina Beate
Stilgenbauer, Stephan
Doehner, Hartmut
Fink, Anna-Maria
Fischer, Kirsten
Wendtner, Clemens-Martin
Hallek, Michael
BLOOD, 2011, 118 (21) : 1233 - 1234
[33] First-Line Treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Randomized Phase III Trial On Behalf of An International Group of Investigators and the German CLL Study Group
Hallek, Michael
Fingerle-Rowson, Guenter
Fink, Anna-Maria
Busch, Raymonde
Mayer, Jiri
Hensel, Manfred
Hopfinger, Georg
Hess, Georg
von Gruenhagen, Ulrich
Bergmann, Manuela A.
Catalano, John
Zinzano, Pier Luigi
Cappio, Federico Caligaris
Seymour, John F.
Berrebi, Alain
Jaeger, Ulrich
Cazin, Bruno
Trneny, Marek
Westermann, Anne
Wendtner, Clemens-Martin
Eichhorst, Barbara F.
Staib, Peter
Boettcher, Sebastian
Ritgen, Matthias
Mendila, Myriam
Kneba, Michael
Doehner, Hartmut
Stilgenbauer, Stephan
Fischer, Kirsten
BLOOD, 2009, 114 (22) : 223 - 224
[34] Chemoimmuno-Therapy with Fludarabine, Cyclophosphamide and Alemtuzumab (FC-Cam) in Patients with Relapsed or Genetic High-Risk CLL: Final Analysis of the CLL2L Trial of the German CLL Study Group
Elter, Thomas
James, Rojin
Stilgenbauer, Stephan
Boettcher, Sebastian
Ritgen, Matthias
Doehner, Hartmut
Hallek, Michael
Engert, Andreas
BLOOD, 2009, 114 (22) : 92 - 92
[35] Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry
Kutsch, Nadine
Giza, Adam
Robrecht, Sandra
Stumpf, Janina
Federhen, Anno
Stoltefuss, Andrea
Vehling-Kaiser, Ursula
Koenigsmann, Michael
Tausch, Eugen
Schneider, Christof
Stilgenbauer, Stephan
Illmer, Thomas
Schlag, Rudolf
Doerfel, Steffen
Gaska, Tobias
Kiehl, Michael
Mueller-Hagen, Sigrun
Moorahrend, Enno
Linde, Hartmut
Schlenska-Lange, Anke
von Tresckow, Julia
Fischer, Kirsten
Eichhorst, Barbara
Hallek, Michael
Fink, Anna Maria
EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 113 (02) : 235 - 241
[36] First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
Eichhorst, Barbara
Fink, Anna-Maria
Bahlo, Jasmin
Busch, Raymonde
Kovacs, Gabor
Maurer, Christian
Lange, Elisabeth
Koeppler, Hubert
Kiehl, Michael
Soekler, Martin
Schlag, Rudolf
Vehling-Kaiser, Ursula
Koechling, Georg
Ploeger, Christoph
Gregor, Michael
Plesner, Torben
Trneny, Marek
Fischer, Kirsten
Doehner, Harmut
Kneba, Michael
Wendtner, Clemens-Martin
Klapper, Wolfram
Kreuzer, Karl-Anton
Stilgenbauer, Stephan
Boettcher, Sebastian
Hallek, Michael
LANCET ONCOLOGY, 2016, 17 (07): : 928 - 942
[37] Planned first efficacy and safety analysis of de-intensified induction with fludarabine, cyclophosphamide plus rituximab (FCR) followed by fludarabine plus rituximab (FR) and remission maintenance therapy with rituximab in previously untreated B-chronic lymphocytic leukemia (B-CLL): The chairos study
Egle, Alexander
Weiss, Lukas
Russ, Gudrun
Thoedtmann, Ralf
Pleyer, Lisa
Gastl, Guenther
Thaler, Josef
Petzer, Andreas
Tinhofer, Inge
Greil, Richard
BLOOD, 2007, 110 (11) : 609A - 609A
[38] The Safety and Tolerability of Oral Fludarabine, ±oral Cyclophosphamide and Iv Rituximab Therapy In Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years - Interim Analysis From the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study
Mulligan, Stephen P.
Gill, Devinder S.
Renwick, William E. P.
Sulda, Melanie L.
Best, O. Giles
Kuss, Bryone J.
Seymour, John F.
BLOOD, 2010, 116 (21) : 308 - 308
[39] Fludarabine, Cyclophosphamide, Rituximab (FCR) and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) - Final Results of a Phase I/II Study
Shadman, Mazyar
Gopal, Ajay K.
Press, Oliver
Maloney, David G.
Mawad, Raya
Wadsworth, Troy
Dennie, Trevor W.
Schultheiss, Karl
Kojouri, Kiarash
Kammerer, Britt E.
Pagel, John M.
BLOOD, 2016, 128 (22)
[40] Low-Dose Fludarabine and Cyclophosphamide Combined with Rituximab In the Treatment of Elderly/Comorbid Patients with chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Preliminary Results of Project Q-Lite by Czech CLL Study Group
Smolej, Lukas
Spacek, Martin
Brychtova, Yvona
Belada, David
Schwarz, Jiri
Doubek, Michael
Motyckova, Monika
Cmunt, Eduard
Rohon, Peter
Klaskova, Katerina
Kozak, Tomas
BLOOD, 2010, 116 (21) : 1024 - 1025

← 1 2 3 4 5 →